The goals and objectives of the Career Development Program (CDP) are to provide training and guidancefor academic physician-scientists, clinician-investigators, and laboratory-based scientists who want todedicate their endeavors to leukemia translational research. To achieve these aims, the CDP will followthese objectives:1. Recruit and train physician, scientists, and senior postdoctoral fellows to become outstandingtranslational investigators in leukemia research;2. Mentor awardees in the latest advances in cancer biology, at both the molecular and cellular level,emphasizing the translational aspects of research;3. Provide environmental and institutional resources that enable the awardees to excel in their respectivefields of research as well as train them to be resourceful in the area of project development andscientific discovery;4. Foster professional growth in the area of translational research by encouraging awardees1 participationin seminars, presentations, conferences both within their parent institution and outside in the scientificcommunity.Lay Description: The goals and objectives of the Career Development Program (CDP) are to providetraining and guidance for academic physician-scientists, clinician-investigators, and laboratory-basedscientists who want to dedicate their endeavors to leukemia translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100632-06
Application #
7468685
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2008-09-01
Budget End
2009-04-30
Support Year
6
Fiscal Year
2008
Total Cost
$92,643
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Fiorini, Elena; Santoni, Andrea; Colla, Simona (2018) Dysfunctional telomeres and hematological disorders. Differentiation 100:1-11
Cortes, Jorge; Perl, Alexander E; Döhner, Hartmut et al. (2018) Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 19:889-903
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Takahashi, Koichi; Wang, Feng; Morita, Kiyomi et al. (2018) Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9:2670
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Kayser, Sabine; Levis, Mark J (2018) Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol 180:484-500
Xia, Fang; Ning, Jing; Huang, Xuelin (2018) Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9:
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12

Showing the most recent 10 out of 487 publications